Summary
Insulin withdrawal studies were performed in 12 Type 1 (insulin-dependent) C-peptide negative diabetic patients with low to moderate insulin antibody levels, to assess the biological availability of antibody-bound insulin and its clinical significance. There was a highly significant correlation between the extent to which the free insulin concentration was maintained during the period of insulin withdrawal and both the level of insulin-binding by serum and the total insulin concentration at the start of the study. During insulin withdrawal, the patients who best maintained their circulating free insulin levels showed the smallest increases in blood glucose and 3-hydroxybutyrate concentrations. We conclude that antibody-bound insulin is available for physiological action, and that in those individuals with moderate antibody concentrations it is capable, in the fasting state, of maintaining free insulin levels. In these circumstances insulin antibodies are behaving as simple carrier proteins.
Article PDF
Similar content being viewed by others
References
Kurtz AB, Nabarro JDN (1980) Circulating insulin-binding antibodies. Diabetologia 19: 329–334
Dixon K, Exon PD, Malins JM (1975) Insulin antibodies and the control of diabetes. Quart J Med 44: 543–553
Gray RS, Borsey DQ, Kurtz A, Rainbow S, Smith AF, Elton RA, Duncan LJP, Clarke BF (1981) Relationship of glycosylated haemoglobin to C-peptide secretory status and antibody binding of insulin in insulin-dependent diabetes. Horm Metab Res 13: 599–603
Faber OK, Binder C (1977) B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment. Diabetologia 13: 263–268
Nakagawa S, Nakayama H, Sasaki T, Yoshino K, Yu YY, Shinozaki K, Aoki S, Mashimo K (1973) A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590–600
Kurtz AB, Matthews JA, Mustaffa BE, Daggett PR, Nabarro JDN (1980) Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin. Diabetologia 18: 147–150
Heding LG, Munkgaard Rasmussen S (1975) Human C-peptide in normal and diabetic subjects. Diabetologia 11: 201–206
Kuzuya H, Blix PM, Horwitz DL, Steiner DR, Rubenstein AH (1977) Determination of free and total insulin and C-peptide in insulin treated diabetics. Diabetes 26: 22–29
Gibbard S, Watkins PJ (1968) A micro-method for the enzymatic determination of D-β-hydroxybutyrate and acetoacetate. Clin ChimActa 19: 511–521
Andersen SB (1964) Metabolism of human gamma globulin. Blackwell Scientific Publications, Oxford
Kruse V (1981) Effect of insulin-binding antibodies on free insulin in plasma and tissue after subcutaneous injection. A model study. In: Keck K, Erb P (ed) Basic and clinical aspects of immunity to insulin, de Gruyter Berlin, New York, pp 319–334
Kurtz AB, Matthews JA, Nabarro JDN (1978) Insulin-binding antibody: reaction differences with bovine and porcine insulins. Diabetologia 15: 19–22
Harwood R (1969) Insulin-binding antibodies and ‘spontaneous’ hypoglycaemia. N Engl J Med 262: 978–979
Nabarro JDN, Mustaffa BE, Morris DV, Walport MJ, Kurtz AB (1979) Insulin deficient diabetes. Diabetologia 16: 5–12
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vaughan, N.J.A., Matthews, J.A., Kurtz, A.B. et al. The bioavailability of circulating antibody-bound insulin following insulin withdrawal in Type I (insulin-dependent) diabetes. Diabetologia 24, 355–358 (1983). https://doi.org/10.1007/BF00251824
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00251824